Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer.
- Resource Type
- Article
- Authors
- Shen, Chia-I; Chao, Heng-Sheng; Shiao, Tsu-Hui; Chiang, Chi-Lu; Huang, Hsu-Ching; Luo, Yung-Hung; Chiu, Chao-Hua; Chen, Yuh-Min
- Source
- Scientific Reports. 8/9/2021, Vol. 11 Issue 1, p1-9. 9p.
- Subject
- *NON-small-cell lung carcinoma
*CANCER chemotherapy
*CANCER immunotherapy
*EPIDERMAL growth factor receptors
*GENETIC mutation
- Language
- ISSN
- 2045-2322
Whether ICIs combined with chemotherapy can improve outcomes in EGFR-mutant non-small cell lung cancer (NSCLC) remains uncertain. Patients with EGFR-mutant NSCLC and who progressed on first-line EGFR-TKIs treatment were retrospectively collected. We reviewed the outcome of these patients treated with ICIs or ICIs combined chemotherapy (ICI + C). Total 30 patients were included. The ORR were 9.1% and 25.0% for the ICI and ICI + C groups. The ICI + C group showed the trend of longer progression-free survival and overall survival periods. Patients without the T790M mutation had a significantly longer PFS than did those without this mutation (4.23 [95% CI: 2.75–5.72] vs. 1.70 [95% CI: 0.00–3.51] months, HR:4.45, p = 0.019). ICIs combined with chemotherapy tended to be more effective than ICIs alone in pretreated EGFR-mutant NSCLC. The T790M mutation may be a potential biomarker. [ABSTRACT FROM AUTHOR]